Value Model

In addition to breakthrough science, this test also has strong economic value:

the total expenditure for topoI inhibitors is estimated at $1.3 billion annually, although most patients don't benefit from the drug (only an estimated 30% of patients responded to treatment). Implementing this diagnostic would result in an estimated 66% cost savings, which is over $1.8 million per 100 patients treated.